End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
-.--% | -.--% |
Jul. 01 | Tarsus Pharmaceuticals, Inc.(NasdaqGS:TARS) dropped from Russell Small Cap Comp Value Index | CI |
Jul. 01 | Tarsus Pharmaceuticals, Inc.(NasdaqGS:TARS) added to Russell Microcap Growth Index | CI |
Financials (USD)
Sales 2024 * | 146M | Sales 2025 * | 270M | Capitalization | 1.08B |
---|---|---|---|---|---|
Net income 2024 * | -139M | Net income 2025 * | -53M | EV / Sales 2024 * | 6.41 x |
Net cash position 2024 * | 142M | Net cash position 2025 * | 115M | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-7.54
x | P/E ratio 2025 * |
-20.1
x | Employees | 244 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.91% |
Latest transcript on Tarsus Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 23-04-23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 20-07-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 16-12-31 |
Wendy Yarno
BRD | Director/Board Member | 68 | 20-11-18 |
Director/Board Member | 69 | 19-11-30 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+33.72% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+11.08% | 234B | |
+15.64% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |